BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies
BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad, a leader in the discovery and development of CAR-T cell therapies. BioLife’s CryoStor clinical grade cell freeze media is incorporated into Celyad’s manufacturing process for its Natural Killer Receptor based T-Cell (NKR-T) platform. In addition, CryoStor and HypoThermosol®, BioLife’s companion cell storage and shipping media, have been used in at least 250 regenerative medicine applications, including several late stage clinical trials. Mike Rice, BioLife President & CEO, commented, “The execution of this new supply agreement further validates the critical role our proprietary biopreservation media products play in the development and commercialization of cellular therapies. We are very pleased to support Celyad in their mission to bring potential life-saving cell-based products to the market.” For additional information; please read the Press Release.